In TRANSCEND-CKD, retatrutide reduced UACR by 49.2% vs placebo and lowered intraglomerular pressure and kidney fat without changing measured GFR at 24 weeks.
News|Articles|July 4, 2025
Q2 2025 Recap: Endocrinology News and Updates
Author(s)Patrick Campbell
Fact checked by: Victoria Johnson
Explore key advancements in endocrinology from Q2 2025, including FDA approvals and groundbreaking diabetes research shaping future treatments.
Advertisement
Advertisement
The second quarter of 2025 brought meaningful developments in endocrinology, from FDA actions to clinical breakthroughs spotlighted at major meetings. Several regulatory milestones signaled progress for patients across the spectrum of endocrine disorders, including expanded access to CGM technology, new formulations for adrenal insufficiency, and a broader treatment label for Cushing’s syndrome.
Related to this article
Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.
Yoseph Dalia, MD, discusses diagnosing and treating pseudofolliculitis barbae, its occupational impact, and barriers to care in skin of color.
Catch up on any data and key clinician perspectives presented at the Heart Failure Society of America Annual Scientific Meeting 2026.
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.
Participants described how payer requirements and documentation of steroid exposure shape biologic access.
Ravulizumab cut proteinuria 43.4% vs placebo at week 34 in I CAN, making it the first C5 inhibitor approved for IgA nephropathy under accelerated approval.
Advertisement
Advertisement